Something I’ve struggled with on and off over the 20 years that I have been making mathematical models is explaining those models to others. I have tried to bring people along and develop their understanding. But mainly what I observed was that, some people just got it and others did not.
I have certainly improved my own skill at explaining. This comes down to having streamlined stories and simpler take-home messages. Telling a clearer story certainly improves my audiences’ self-satisfaction, but ultimately some of them get the whole message and others do not.
I had the opportunity to interview for a senior position at a very big company recently. The entire process was fascinating for what it says about human nature and about large companies. The outcome of the process is unclear at the time of writing this but I am expecting the intrinsic misalignments in the process will lead it into the reeds from which it is unlikely to emerge. I am as close to the perfect candidate for the role that they will ever interview, but the internal parties are not all aligned around the very existence of the position.
I had quite a nice spring season of talks planned for 2020. I was invited to deliver a keynote on AI in Healthcare at Biovaria. And, I was one of the invited speakers for the Dynamics of Immune Repertoires conference where I would also have given a workshop, in Dresden. Covid-19 struck and the rest is history.
Emergencies lead to quick changes of plans. Anthony Kelly from AI in Action reached out to me asking me to take part in a special on AI in Healthcare.
I have been reconnecting with some of my academic friends. We all belong more or less to the same age cohort. In recent weeks, I have been watching them interacting with one another on Twitter and through various other media. They each have achieved considerable degrees of success in their chosen fields – all have tenure at global top-50 ranked institutions. Through my observations, I have come to the realisation that the era of the solo contributor is dead.
Working in industrial research is usually very motivating but occasionally it is also frustrating. You’ve just done something really cool but you’re not allowed to tell anybody outside the company about it. Indeed, in a small company there might not be anybody inside of the company who can even appreciate it!
I have worked on roughly 4 really cool projects since leaving academia at the end of 2017. And apart from some basic mentions in my blog (e.g. here and here) most of what I have done has been known only to a few key stakeholders.
There is a growing awareness in the field of immunology of the potential for using mathematical techniques. The wedge-issue here is the cascade of data appearing via new cytometry techniques; large-data looks like a math issue to most people. I of course come from the other side of a spectrum – everything looks like a math issue to me – I wanted to stimulate drug development which engages with immune system dynamics by founding my company.
First a mea culpa, I have a huge backlog of relatively heavy articles that I really want to add to the blog. But I’ve been busy getting married – congratulations to me – and I didn’t have enough time. I strongly believe in following relatively strict guidelines on writing and editing articles, where I set myself deadlines and avoid over-writing on topics – it is just a blog after all – but for deep insights I do also have a minimum standard that I want to be able to produce before I’m willing to hit the Publish button.
Today is my last official day under contract to Fosanis GmbH. I had my first encounter with the founders following my talk at the Digital Health Forum in March 2018. Following that initial meeting I became an advisor, writing a major funding proposal, bringing scientific techniques to the core of the product. In November 2018, following the closure of my own company, I became a full-time member of staff – as Head of Data Science – and led the project on the basis of the ideas contained in my funding proposal.